Shampoo shows promise for scalp psoriasis in small study
NCT ID NCT06771648
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested Daxxin Psoriasis Shampoo in 41 adults with moderate scalp psoriasis. Participants used the shampoo 3 to 7 times a week for 6 weeks. The goal was to see if it reduced scalp redness, thickness, and scaling, and improved quality of life. Results showed most people had at least some improvement.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Daxxin Psoriasis Shampoo (a medicated shampoo device)
- What this could lead to
- If it works, this shampoo could offer a safe, easy-to-use option for managing scalp psoriasis at home.
- What could go wrong
- This was a small, single-site study with no comparison group, so results may not apply to everyone. The shampoo is already on the market, so this is a routine check, not a breakthrough.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
41 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Dec 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female ≥18 years old 2. Clinical diagnosis of moderate scalp psoriasis assessed by Psoriasis Scalp Severity Index (PSSI, moderate = 3-10) 3. At least a score of 1 grade for each symptom erythema, induration and desquamation 4. Subject is willing and able to use Daxxin Psoriasis Shampoo as directed, comply with investigation instructions, and commit to all follow-up visits for the duration of the investigation, as judged by the Investigator 5. Subject agrees to refrain from using other treatments for scalp psoriasis during the clinical investigation 6. Subject is willing and able to provide written informed consent Exclusion Criteria: 1. Known allergy or sensitivity to any component of the device 2. Use of psoriasis shampoo 2 weeks prior to enrolment 3. Use of other psoriasis scalp treatment i.e., Betnovate that could affect the study result within 4 weeks prior to enrolment 4. Use of systemic and/or biological treatment for psoriasis 5. Subject has a history of psoriasis unresponsive to topical treatments 6. Subject is pregnant, lactating at time of enrolment, or is planning to become pregnant during the study 7. Subjects with any other condition that, as judged by the investigator, may make investigation procedures inappropriate 8. Subject with alcohol or drug abuse
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Scalp psoriasis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CTC
Mölndal, 431 53, Sweden
-
Enheten för kliniska studier, University Hospital Region Örebro
Örebro, 70362, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.